Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 5/20 | 0.35 |
| ▸ | FNTB | P49356 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885001 | 1.00 | POLB (0.36) | POLBFNTAFNTBHDAC1HDAC6 | |
| SCHEMBL10286051 | 0.84 | POLB (0.36) | POLBFNTAFNTBHDAC1HDAC6 | |
| SCHEMBL2147611 | 0.81 | CHRM4 (0.41) | FNTAFNTBHDAC1HDAC6TRPV1 | |
| SCHEMBL829076 | 0.76 | POLB (0.40) | POLB | |
| SCHEMBL10286472 | 0.76 | HDAC1 (0.44) | FNTAFNTBHDAC1HDAC6P2RX7 | |
| SCHEMBL3312248 | 0.76 | HDAC1 (0.44) | FNTAFNTBHDAC1HDAC6P2RX7 | |
| SCHEMBL10286029 | 0.76 | POLB (0.42) | POLBP2RX7 | |
| SCHEMBL4713765 | 0.75 | HDAC1 (0.43) | FNTAFNTBHDAC1HDAC6P2RX7 | |
| SCHEMBL828603 | 0.75 | TBXAS1 (0.47) | POLBTRPV1P2RX7 | |
| SCHEMBL11983384 | 0.72 | FNTA (0.40) | FNTAFNTBHDAC1HDAC6TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | POLB 4654/4885FNTA 4519/4885FNTB 4285/4885 |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | POLB 4654/4885FNTA 4519/4885FNTB 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.